Latest Health News

Etherstack plc reports a record-breaking FY25 with revenues up 62%, driven by major US and UK contracts, and projects continued strong growth into FY26 and beyond.

Bendigo and Adelaide Bank’s latest Basel III disclosures reveal a slight dip in capital ratios offset by improved liquidity and funding stability for the quarter ended September 2025.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

NRW Holdings showcased strong FY25 proforma results and ambitious FY26 guidance at the UBS Conference, underpinned by strategic acquisitions and a diversified portfolio. The company’s growth strategy focuses on expanding capabilities in energy transition and infrastructure markets across Australia, New Zealand, and North America.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Regal Asian Investments Limited has announced an on-market buy-back of its ordinary shares, set to run from November 2025 through November 2026, signaling a strategic move to manage its capital structure.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.

Trading in Alliance Aviation Services Limited (AQZ) shares has resumed following the lifting of a suspension tied to a recent trading update announcement.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Group 6 Metals has materially improved its debt position by converting warrants under its April 2025 recapitalisation plan, signaling renewed shareholder confidence and operational momentum.